Accéder au contenu
Merck

Hybrid Antimicrobial Hydrogel as Injectable Therapeutics for Oral Infection Ablation.

Biomacromolecules (2020-08-14)
Juliana S Ribeiro, Arwa Daghrery, Nileshkumar Dubey, Christina Li, Ling Mei, J Christopher Fenno, Anna Schwendeman, Zeynep Aytac, Marco C Bottino
RÉSUMÉ

Oral bacterial infection represents the leading cause of the gradual destruction of tooth and periodontal structures anchoring the teeth. Lately, injectable hydrogels have gained increased attention as a promising minimally invasive platform for localized delivery of personalized therapeutics. Here, an injectable and photocrosslinkable gelatin methacryloyl (GelMA) hydrogel is successfully engineered with ciprofloxacin (CIP)-eluting short nanofibers for oral infection ablation. For this purpose, CIP or its β-cyclodextrin (β-CD)-inclusion complex (CIP/β-CD-IC) has been incorporated into polymeric electrospun fibers, which were subsequently cut into short nanofibers, and then embedded in GelMA to obtain an injectable hybrid antimicrobial hydrogel. Thanks to the solubility enhancement of CIP by β-CD-IC and the tunable degradation profile of GelMA, the hydrogels promote localized, sustained, and yet effective cell-friendly antibiotic doses, as measured by a series of bacterial assays that demonstrated efficacy in attenuating the growth of Gram-positive Enterococcus faecalis. Altogether, we foresee significant potential in translating this innovative hybrid hydrogel as an injectable platform technology that may have broad applications in oral infection ablation, such as periodontal disease and pulpal pathology.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lithium phenyl-2,4,6-trimethylbenzoylphosphinate, ≥95%